Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabigatran versus warfarin for secondary prevention after atrial fibrillation-related acute ischemic stroke or TIA
ChiCTR-IPR-17011973Phase 4Recruiting
- Sponsor
- The 2nd Affiliated Hospital of Harbin Medical University
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in ischemic stroke, transient ischaemic attack (TIA) and Atrial fibrillation (AFib) comparing Dabigatran etexilate group with Warfarin group (2 arms). Primary endpoints: HAS-BLED score, Modified Rankin Scale score and 6 more. Started Jul 2017; status: recruiting.
02
Drugs
dabigatranwarfarin
03
Conditions
ischemic stroketransient ischaemic attack (TIA)Atrial fibrillation (AFib)
Beyond the preview
Go deeper on ChiCTR-IPR-17011973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17011973.